X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1067) 1067
humans (834) 834
type 2 diabetes (739) 739
dpp-4 inhibitor (647) 647
diabetes mellitus, type 2 - drug therapy (641) 641
dpp-4 inhibitors (609) 609
diabetes (510) 510
endocrinology & metabolism (494) 494
male (483) 483
dipeptidyl-peptidase iv inhibitors - therapeutic use (418) 418
sitagliptin (399) 399
hypoglycemic agents - therapeutic use (381) 381
glucagon-like peptide-1 (373) 373
female (366) 366
animals (328) 328
middle aged (319) 319
dpp-4 (314) 314
glucose (309) 309
metformin (307) 307
pharmacology & pharmacy (307) 307
double-blind (277) 277
dipeptidyl peptidase-4 inhibitor (276) 276
glycemic control (265) 265
glp-1 (258) 258
aged (248) 248
treatment outcome (244) 244
vildagliptin (240) 240
type 2 diabetes mellitus (239) 239
diabetes mellitus (237) 237
dipeptidyl-peptidase iv inhibitors - pharmacology (231) 231
insulin (222) 222
diabetes mellitus, type 2 - blood (207) 207
type-2 diabetes-mellitus (203) 203
hypoglycemic agents (200) 200
safety (199) 199
adult (194) 194
linagliptin (193) 193
dipeptidyl peptidase-4 inhibitors (190) 190
dipeptidyl-peptidase iv inhibitors - adverse effects (178) 178
drug therapy (173) 173
hypoglycemic agents - adverse effects (172) 172
efficacy (170) 170
adamantane - analogs & derivatives (168) 168
diabetes therapy (167) 167
blood glucose - drug effects (165) 165
dextrose (164) 164
internal medicine (164) 164
analysis (162) 162
care and treatment (161) 161
drug therapy, combination (159) 159
blood glucose - metabolism (157) 157
beta-cell function (156) 156
hypoglycemic agents - administration & dosage (149) 149
incretin (146) 146
dipeptidyl peptidase 4 - metabolism (142) 142
glucagon (141) 141
saxagliptin (141) 141
hypoglycemic agents - pharmacology (140) 140
mellitus (140) 140
mice (139) 139
dipeptidyl-peptidase iv inhibitors - administration & dosage (136) 136
medicine & public health (135) 135
double-blind method (125) 125
glycated hemoglobin a - metabolism (125) 125
hypoglycemia (124) 124
improves glycemic control (124) 124
rats (124) 124
sitagliptin phosphate (123) 123
medicine, general & internal (121) 121
pharmacokinetics (115) 115
incretins (113) 113
review (113) 113
risk factors (113) 113
diabetes mellitus, type 2 - complications (112) 112
research (112) 112
peptidase (111) 111
clinical trials (104) 104
hyperglycemia (101) 101
peptides (101) 101
therapy (101) 101
diabetes mellitus, type 2 - metabolism (100) 100
insulin resistance (100) 100
metformin - therapeutic use (98) 98
cardiac & cardiovascular systems (96) 96
oxidative stress (96) 96
adamantane - therapeutic use (95) 95
chemistry, medicinal (94) 94
glycosylated hemoglobin (92) 92
glp-1 receptor agonists (91) 91
liraglutide (90) 90
medicine, research & experimental (90) 90
dipeptidyl peptidase-4 (89) 89
alogliptin (86) 86
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (86) 86
dosage and administration (85) 85
health aspects (85) 85
dpp-4 inhibition (84) 84
biochemistry & molecular biology (83) 83
mortality (81) 81
drug-naive patients (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1664) 1664
German (32) 32
Japanese (32) 32
French (25) 25
Spanish (19) 19
Czech (11) 11
Korean (9) 9
Italian (5) 5
Polish (5) 5
Russian (5) 5
Chinese (4) 4
Hungarian (2) 2
Slovak (2) 2
Turkish (2) 2
Arabic (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic Research, ISSN 0289-8020, 2013, Volume 34, Issue 7, pp. 985 - 989
Journal Article
Internal Medicine, ISSN 0918-2918, 2017
Objective We investigated the efficacy, safety, and patient satisfaction of once-weekly DPP-4 inhibitors (DPP-4Is). Methods Either of two once-weekly DPP-4Is,... 
treatment satisfaction | DPP-4 inhibitor
Journal Article
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 04/2012, Volume 28, Issue 4, pp. 513 - 523
Journal Article
DIABETES OBESITY & METABOLISM, ISSN 1462-8902, 06/2017, Volume 19, Issue 6, pp. 831 - 841
Aims: To investigate the association of novel oral glucose-lowering drugs (GLDs), compared with that of insulin, with risk of all-cause mortality,... 
cardiovascular disease | hypoglycaemia | SAFETY | dapagliflozin | HEART-FAILURE | MELLITUS | METFORMIN TREATMENT | pharmacoepidemiology | type 2 diabetes | PRIMARY-CARE | THERAPY | SULFONYLUREAS | DPP-4 inhibitor | ENDOCRINOLOGY & METABOLISM | WEIGHT-GAIN | DPP-4 INHIBITORS | OUTCOMES
Journal Article
Therapeutic Research, ISSN 0289-8020, 2014, Volume 35, Issue 12, pp. 1103 - 1106
Journal Article
Current Diabetes Reviews, ISSN 1573-3998, 01/2014, Volume 10, Issue 4, pp. 238 - 250
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 10/2016, Volume 36, Issue 10, pp. 2125 - 2132
Journal Article
11/2010
This study characterized the effects of two anti-diabetic drugs, a thiazolidinedione (TZD) and a Dipeptidyl Peptidase-4 (DPP-4) inhibitor on bone quality in a... 
Bone Quality | Osteoporosis | DPP-4 Inhibitors | 0566 | 0794 | 0571 | Diabetes | Thiazolidinediones
Dissertation
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 09/2017, Volume 5, Issue 9, pp. 709 - 717
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 02/2019, Volume 27, Issue 4, pp. 644 - 654
Dipeptidyl Peptidase-IV (DPP-4) is a validated therapeutic target for type 2 diabetes. Aiming to interact with both residues Try629 and Lys554 in S ′ site, a... 
Benzoic acid | T2DM | Uracil derivatives | DPP-4 inhibitor | DESIGN | CHEMISTRY, MEDICINAL | SAXAGLIPTIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | ALPHA | DISCOVERY | MASS | BIOLOGICAL EVALUATION | PANCREATIC BETA-CELL | DPP-4 INHIBITORS | TYPE-2 DIABETES-MELLITUS | Type 2 diabetes | Pyrimidines | Organic acids
Journal Article
Archives of Physiology and Biochemistry, ISSN 1381-3455, 06/2018, pp. 1 - 9
We tested the hypothesis that glucocorticoid (GC) exposure in female rats would lead to glucose dysregulation and elevated cardiac inflammatory biomarkers,... 
DPP-4 | glucose homeostasis | VCAM-1 | GSK-3 | Dexamethasone
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk... 
cardiovascular disease | type 2 diabetes | DPP | hypoglycaemia | dapagliflozin | diabetes complications | 4 inhibitor | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | DPP‐4 inhibitor | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Synthetic Communications, ISSN 0039-7911, 08/2016, Volume 46, Issue 15, pp. 1307 - 1317
DPP-4 inhibition is one of the most extensively explored approaches for the management of type 2 diabetes (T2D). Most DPP-4 inhibitors in the market contain a... 
non-proline mimetic | sulfonamide | DPP-4 inhibitor | Diamide | POTENT | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | BIOLOGY | CHEMISTRY, ORGANIC | MECHANISMS | DPP-4 INHIBITORS
Journal Article
Hormone and Metabolic Research, ISSN 0018-5043, 05/2015, Volume 48, Issue 1, pp. 70 - 75
Journal Article
Journal of Atherosclerosis and Thrombosis, ISSN 1340-3478, 2017
Aim: The morbidity of cardiovascular disease in patients with type 2 diabetes mellitus (DM) deteriorates in combination with dyslipidemia. The accumulation of... 
Remnants | DPP-4 | Sitagliptin | Lipoprotein Profile | Postprandial hypertriglyceridemia
Journal Article
Cancer Research, ISSN 0008-5472, 02/2019, Volume 79, Issue 4, pp. 735 - 746
Dipeptidyl peptidase (DPP)-4 is a multifunctional glycoprotein involved in various biological and pathologic processes. DPP-4 has been widely recognized as a... 
MAMMALIAN TARGET | CELLS | ONCOLOGY | PATHWAY | COLORECTAL-CANCER | PREVENTION | CXCR4 | DPP-4 INHIBITORS | EXPRESSION | CARCINOMA
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.